Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation
1996

Effects of C-1311 on Cancer Cells

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): J Lamb, DN Wheatley

Primary Institution: University Medical School, Foresterhill, Aberdeen, UK

Hypothesis

Does the imidazoacridinone C-1311 induce cell death in cancer cells through specific cell cycle perturbations?

Conclusion

High doses of C-1311 do not necessarily lead to increased cell death, highlighting the importance of the G2/M transition in the cell death process.

Supporting Evidence

  • C-1311 induced a complete G2 arrest in HeLa cells at specific concentrations.
  • High doses of C-1311 led to S-phase accumulation, which inhibited cell death.
  • Cell death was associated with activation of the p34cdc2/cyclin B complex.

Takeaway

C-1311 is a drug that can stop cancer cells from growing, but too much of it can actually protect the cells instead of killing them.

Methodology

HeLa S3 cells were treated with varying concentrations of C-1311, and cell cycle effects were analyzed using flow cytometry and growth inhibition assays.

Limitations

The study primarily focused on HeLa cells, which may not represent all cancer types.

Participant Demographics

HeLa S3 cells (human cervical cancer cells) and normal human diploid fibroblasts.

Statistical Information

P-Value

0.018+0.003

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication